Call us: + 31 (0)20 - 4350 580

Home > News > Articles & whitepapers > Comparison of Phase I/II trials regarding antig...

Comparison of Phase I/II trials regarding antigen-specific versus non-specific anticancer immunotherapies

Comparison of Phase I/II trials regarding antigen-specific versus non-specific anticancer immunotherapies

Antigen-specific immunotherapy targets particular tumour associated antigens in order to address and eradicate solely tumour-marker defined cancer cells. In contrast, non-specific agents generally stimulate the immune system by for example reversal of immune suppression, or activation of innate immunity for a better anti-cancer immune response. We investigated whether differences among these two classes are reflected in patient selection, objectives and results of Phase I/II studies.

[...]

Please find the poster here.